Drug cocktail shows promise for Hard-to-Treat cancers
NCT ID NCT03911557
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 28 times
Summary
This study tested a combination of two immunotherapy drugs (durvalumab and tremelimumab) in 14 adults with advanced solid tumors that had a high number of genetic mutations. The goal was to see if this treatment could slow cancer growth compared to their prior therapy. Participants had not received similar immunotherapy before.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Markey Cancer Center
Lexington, Kentucky, 40536, United States
Conditions
Explore the condition pages connected to this study.